Literature DB >> 17267591

Use of an inhibition enzyme-linked immunosorbent assay for quantification of capsular polysaccharide or proteins in vaccines.

Thomas J Inzana1, Anna Champion.   

Abstract

An inhibition enzyme-linked immunosorbent assay (ELISA) is described for quantification of capsular polysaccharide or proteins in vaccines and other samples containing whole cells or extracts of Actinobacillus pleuropneumoniae. The assay can be used to quantify any antigen that can be purified and for which highly specific antibodies are not available. The assay can be carried out by any laboratory capable of performing an ELISA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267591      PMCID: PMC1828856          DOI: 10.1128/CVI.00302-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

1.  Production of RNA-dependent haemolysin by Haemophilus pleuropneumoniae.

Authors:  P G Martin; P Lachance; D F Niven
Journal:  Can J Microbiol       Date:  1985-05       Impact factor: 2.419

2.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

Review 3.  Virulence in Actinobacillus pleuropneumoniae and RTX toxins.

Authors:  J Frey
Journal:  Trends Microbiol       Date:  1995-07       Impact factor: 17.079

4.  Intrinsic tritium labeling of the capsular polysaccharide antigen of Haemophilus influenzae type B.

Authors:  P Anderson
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

5.  Serotype specificity and immunogenicity of the capsular polymer of Haemophilus pleuropneumoniae serotype 5.

Authors:  T J Inzana; B Mathison
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

6.  Serologic detection of Actinobacillus pleuropneumoniae in swine by capsular polysaccharide-biotin-streptavidin enzyme-linked immunosorbent assay.

Authors:  T J Inzana; B Fenwick
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  Purification and partial characterization of the capsular polymer of Haemophilus pleuropneumoniae serotype 5.

Authors:  T J Inzana
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

8.  Biotinylation of bacterial lipopolysaccharide and its applications to electron microscopy.

Authors:  C O Odeyale; Y H Kang
Journal:  J Histochem Cytochem       Date:  1988-09       Impact factor: 2.479

9.  Haemophilus parahaemolyticus serotypes. Pathogenicity and cross immunity.

Authors:  R Nielsen
Journal:  Nord Vet Med       Date:  1979-10

10.  Haemophilus pleuropneumoniae serotypes--cross protection experiments.

Authors:  R Nielsen
Journal:  Nord Vet Med       Date:  1984 Jul-Aug
View more
  4 in total

1.  Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development.

Authors:  Yang Zhou; Lu Li; Zhaohui Chen; Hong Yuan; Huanchun Chen; Rui Zhou
Journal:  Clin Vaccine Immunol       Date:  2012-12-26

2.  Gamma-irradiation of Streptococcus pneumoniae for the use as an immunogenic whole cell vaccine.

Authors:  Min Yong Jwa; Soyoung Jeong; Eun Byeol Ko; A Reum Kim; Hyun Young Kim; Sun Kyung Kim; Ho Seong Seo; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Microbiol       Date:  2018-07-25       Impact factor: 3.422

3.  Draft Genome Sequences of Six Actinobacillus pleuropneumoniae Serotype 8 Brazilian Clinical Isolates: Insight into New Applications.

Authors:  Monalessa Fábia Pereira; Ciro César Rossi; Fabíola Marques de Carvalho; Luiz Gonzaga Paula de Almeida; Rangel Celso Souza; Ana Tereza Ribeiro de Vasconcelos; Denise Mara Soares Bazzolli
Journal:  Genome Announc       Date:  2015-03-05

4.  Immune Responses to Irradiated Pneumococcal Whole Cell Vaccine.

Authors:  Eunbyeol Ko; Soyoung Jeong; Min Yong Jwa; A Reum Kim; Ye-Eun Ha; Sun Kyung Kim; Sungho Jeong; Ki Bum Ahn; Ho Seong Seo; Cheol-Heui Yun; Seung Hyun Han
Journal:  Vaccines (Basel)       Date:  2021-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.